Status
Conditions
Treatments
Study type
Funder types
Identifiers
About
Single-center nonrandomized single-arm early feasibility study of participants with soft tissue trauma in the hand. Prior to enrolling participants with hand injuries, the safety of continuous glove use for up to 96 hours without a glove replacement will be assessed on healthy volunteers.
Injured participants will be on study for up to 7 weeks depending on when the final glove is removed.
Screening: Prior to surgery and through 72 hours post-surgery to identify eligible patients
Treatment with Glove: Treatment begins with initial application of the ReHeal Glove and can last up to 7 days (with dressing changes every 48-72 hours unless more frequent changes are requested by the treating physician.)
Follow-up: Up to 6 weeks after final removal of glove to ensure complete wound healing.
Full description
A maximum of 10 participants may be enrolled. Each participants will be enrolled sequentially, with in-depth review of study data from each individual participant before proceeding to the next participant. There will be one and only one participant at a time experiencing glove use. This allows the study team to identify and correct any safety issues before another participant is enrolled and begins glove use. This strategy is in place to minimize risk to participants. Screening data will be reviewed to determine participant eligibility. Participants who meet all inclusion criteria and none of the exclusion criteria will be entered into the study.
Each participant will have the glove applied after surgery. The timing of the initial application could be immediately following surgery or up to 3 days after the surgery, at the discretion of the treating surgeon. Application delays of 1-3 days may be indicated if, in the opinion of the surgeon, the wound would benefit from a period of immobilization prior to donning the glove and allowing for the additional mobility possible with the glove dressing.
Reasons for a potential delay could include minimizing bleeding or oozing after debridement, or for protection of a skin graft. Following current standards of negative pressure wound therapy (NPWT), the wound will be assessed and the glove replaced every 48 to 72 hours. The glove may be assessed by the clinical care team and, if needed, removed and replaced earlier. At each participant encounter, data will be collected by the study team and pressure settings will be documented. At each study visit involving a dressing change, the glove will be removed for closer assessment of the wound and replaced with a new glove. Participants will remain in the study until wound healing or clinical resolution, or study exit. After study exit for each participant, data will be reviewed, and any design changes indicated by the results of the study will be implemented prior to enrollment of the next subject.
The ReHeal Glove and Cardinal Health Negative Pressure Wound Therapy Pro/Pro To Go pump will be used.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
• Persons 22 years or older
Wound size greater than 1cm2
Patient will have surgery to treat the wound, warranting the use of a dressing after surgery
Patient must be able to give informed consent
Persons who can read and write in English
Acute, unilateral, and isolated open finger or hand injuries caused by:
Exclusion criteria
• Polytrauma outside of the hand
Malignancy in the wound
Patient undergoing active chemotherapy
Hand wound with any untreated infection
Contaminated wounds not yet debrided
Insensate hand
Non-debrided tunneling wounds
Necrotizing soft-tissue infections
Osteomyelitis
Fractures requiring stabilization.
Untreated non-enteric fistulas
Smoker
Hemophiliac
Sepsis
Active cellulitis in the wound area
Radiation applied directly to the wound
Patients with allergies to product components: silicone, silicone adhesives and polyurethane films (direct contact with wounds), acrylic adhesives (direct contact with skin), polyethylene fabrics, and super-absorbent powders (polyacrylates within the dressing).
Patients chronically treated with any of the following medications:
Primary purpose
Allocation
Interventional model
Masking
10 participants in 1 patient group
Loading...
Central trial contact
Karen Adams
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal